CLDX Q3 2020 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$668,000+22.3% YoY

Gross Profit

-$10M-1503.0% margin

Operating Income

-$14M-2147.0% margin

Net Income

-$14M-2129.3% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+183.1%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$256M

Total Liabilities

$26M

Stockholders' Equity

$230M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$668,000	$546,000	+22.3%
Gross Profit	-$10M	-$11M	+4.9%
Operating Income	-$14M	-$12M	-21.1%
Net Income	-$14M	-$11M	-24.6%

Revenue Segments

Grant

$656,00098%

Service

$12,0002%